Dementia: general overview
|
|
- Myrtle Hunter
- 5 years ago
- Views:
Transcription
1 132 CHAPTER 5 Organic illness Dementia: general overview Essence Dementia is a syndrome characterized by progressive, usually irreversible, global cognitive deficits. Often memory impairment is the first symptom with progression to other defi cits including dysphasia, agnosia, apraxia, impaired executive function, and personality disintegration. For a diagnosis to be made there must be significant impairment of normal functioning and other possible diagnoses (see Differential diagnosis b p. 133), particularly delirium or depression, should be excluded. Common causes Alzheimer s disease (62%), vascular dementia (15%), mixed (10%), Lewy body dementia (4%), fronto-temporal dementia (2%), other (3%). Reversible causes (15%): subdural haematoma, NPH, vitamin B 12 deficiency, metabolic causes, hypothyroidism. Aetiology Parenchymal/degenerative Alzheimer s disease; vascular dementia; fronto-temporal dementia (including Pick s disease); Parkinson s disease; Huntington s disease; Wilson s disease; MS; motor neurone disease (MND); Lewy body disease; progressive supranuclear palsy; corticobasal degeneration. Intracranial Tumour; head trauma; subdural haematoma; CVA; normal pressure hydrocephalus (NPH). Infection Creutzfeldt Jakob disease (prion disease); neurosyphilis; HIV-associated dementia; tuberculosis (TB); subacute sclerosing panencephalitis (SSPE); other. Endocrine Hypothyroidism; hyperparathyroidism; Cushing s and Addison s disease. Metabolic Uraemia; hepatic encephalopathy; hypoglycaemia; calcium imbalance; magnesium imbalance; electrolyte imbalance. Vitamin deficiency B 12 ; folate; pellagra (niacin); thiamine. Toxins Prolonged alcohol misuse; heavy metal poisoning. Clinical features (see Box 5.1) Memory impairment: starts with short-term and progresses to longterm. History of personality change, forgetfulness, social withdrawal, lability of affect, disinhibition, silliness, diminished self-care, apathy, fatigue, deteriorating executive functioning. Other specific cognitive deficits are seen in cortical dementias (see b p. 133). Hallucinations and delusions often paranoid (20 40%) and poorly systematized. Anxiety and/or depression in 50%. Neurological features (e.g. seizures, focal defi cits, primitive reflexes, pseudobulbar palsy, long-tract signs). Catastrophic reaction, ( b p. 88). Pathological emotion spontaneous lability. Sundowner syndrome as evening approaches confusion increases and falls become common.
2 DEMENTIA: GENERAL OVERVIEW 133 Differential diagnosis Delirium; depression (pseudodementia b p. 520); amnestic disorders (b p. 148); learning disability (LD); psychotic disorders; normal ageing (b p. 514). Investigations Include: FBC; LFT; U&E; glucose; erythrocyte sedimentation rate (ESR); thyroid-stimulating hormone (TSH); calcium; magnesium; phosphate; Venereal Disease Research Laboratory (VDRL) test for syphilis; HIV; vitamin B 12 and folate; C-reactive protein; blood culture; LP; EEG; chest X-ray (CXR); ECG; CT (optima and axial protocol); MRI; SPECT. Principles of management Assessment: diagnostic, functional, and social. Cognitive enhancement: acetylcholinesterase inhibitors (tacrine; donepezil; rivastigmine); antioxidants (selegiline, vitamin E);? hormonal (oestrogen; HRT). Treat psychosis/agitation: consider antipsychotics. Treat depression/insomnia: SSRIs; hypnotics. Treat medical illness. Psychological support: to both patient and care-givers. Functional management: maximize mobility; encourage independence with self-care, toilet, and feeding; assist with communication. Social management: accommodation; activities; financial matters; legal matters (power of attorney, wills, and curatorship). Box 5.1 Clinical syndromes of dementia Dementias may be classified in terms of primary site of pathology. Since site of pathology in the brain correlates with neuropsychiatric symptomatology, this is a useful system of classification. 1. Cortical dementias involve primarily the cortex and are divided into: Fronto-temporal e.g. Pick s disease (p. 142). Characterized by prominent personality change which may manifest as a frontal lobe syndrome. A common cause of early-onset dementia, it is often undiagnosed. Language impairments tend to involve reduction in content (semantic anomia). CT shows fronto-temporal atrophy and SPECT shows fronto-temporal metabolism. Posterior parietal e.g. Alzheimer s disease (p. 134). Characterized by early memory loss and focal cognitive deficits. Personality changes are later manifestations. Language impairments involve problems with word-finding (lexical anomia). CT (optima protocol) shows thinning (<12 mm) of the cortex of the medial temporal lobe. 2. Subcortical dementias Parkinson s disease (p. 168); Huntington s disease (p. 170); Wilson s disease (p. 171); Binswanger encephalopathy (p. 144); progressive supranuclear palsy (PSNP) (p. 167); HIV-associated dementia (p. 163); NPH (p. 150). Clinical features: gross psychomotor slowing; depressed mood; movement disorders; mild amnesia; and personality changes. 3. Cortical subcortical dementias e.g. Lewy body dementia (p. 140). Clinical features: cortical and subcortical symptoms. 4. Multifocal dementias e.g. CJD (p. 146). Clinical features: rapid onset and course; involves cerebellum and subcortical structures.
3 134 CHAPTER 5 Organic illness Alzheimer s disease 1 Also termed dementia of the Alzheimer type (DAT), this is the most common cause (70%) of dementia in older people. It is a degenerative disease of the brain with prominent cognitive and behavioural impairment that is suffi ciently severe to interfere signifi cantly with social and occupational function. It affects approximately people in the UK and more than 30 million worldwide. A larger number of people have less severe impairments that usually evolve into the full disorder with time. The percentage of the total population aged over 65 is increasing in the developed world, meaning that the burden of DAT-related health care is likely to increase. Epidemiology Risk of DAT increases with age: 1% at age 60yrs; doubles every 5yrs; 40% of those aged 85yrs. Age-specific incidence is the same for men and women approximately 50% excess prevalence in women (explained by the greater number of at-risk women given their longer lifespan). Risk factors include: Down s syndrome, previous head injury, or hypothyroidism; family history of Down s syndrome, Parkinson s disease, or DAT. Possible protective factors Smoking; oestrogen (e.g. hormone replacement therapy [HRT]); non-steroidal anti-inflammatory drugs (NSAIDs); vitamin E; higher level of pre-morbid education. Pathophysiology Amyloid plaques insoluble β-amyloid peptide deposits as senile plaques or β-pleated sheets in the hippocampus, amygdala, and cerebral cortex. Increased density with advanced disease. Neurofibrillary tangles (NFTs) consist of phosphorylated tau protein and are found in the cortex, hippocampus, and substantia nigra. (NFTs also found in normal ageing, Down s syndrome, dementia pugilistica, and progressive supranuclear palsy.) However, even low densities of NFTs in the cortices of the medial temporal lobes should be considered abnormal. The co-occurrence of amyloid plaques and NFTs was described by Alois Alzheimer in his original description of the disorder and is now accepted universally as a hallmark of the disease. Up to 50% loss of neurons and synapses in the cortex and hippocampus. Genetics: 40% have a positive family history of DAT (esp. early onset: <55yrs). Autosomal dominant inheritance affects <1% of those with dementia. Chromosome 21 the gene for amyloid precursor protein (APP) is found on the long arm. Also implicated in Down s syndrome. Chromosome 19 codes for apolipoprotein E4. Presence of E4 alleles increases risk of DAT; some 15% of Europeans carry the allele.
4 ALZHEIMER S DISEASE Chromosome 14 codes for presenilin 1 (implicated in B-amyloid peptide). Chromosome 1 codes for presenilin 11 (implicated in B-amyloid peptide). Cholinergic hypothesis: the pathological changes lead to degeneration of cholinergic nuclei in the basal forebrain (nucleus basalis of Meynert). This results in dcortical acetylcholine (ACh). Pray, do not mock me: I am a very foolish fond old man, Fourscore and upward, not an hour more or less; And, to deal plainly, I fear I am not in my perfect mind. Methinks I should know you and know this man; Yet I am doubtful: for I am mainly ignorant what place this is, and all the skill I have remembers not these garments; nor I know not where I did lodge last night. Do not laugh at me; For as I am a man, I think this lady to be my child Cordelia. Shakespeare: King Lear, Act II Scene 7
5 136 CHAPTER 5 Organic illness Alzheimer s disease 2 Clinical features Symptoms usually start insidiously but fi rst presentation may be related to an identifiable life event. Early symptoms Failing memory (with disorientation being common, especially for time), muddled effi ciency with activities of daily living (ADLs), spatial dysfunction, and changes in behaviour such as wandering and irritability. By the time the patient presents to clinicians, cognitive deficits are usually apparent. Middle symptoms Intellectual and personality deterioration aphasia, apraxia (evidenced by awkwardness with the sequence of dressing), and agnosia (inability to recognize parts of the body). Occasionally, a patient may present with Gerstmann syndrome (b p. 73), indicating right parietal disease, characterized by finger agnosia, R/L disorientation, acalculia, and dysgraphia), BPSD (behavioural and psychological symptoms in dementia). Impaired visuospatial skills and executive function are common. Late symptoms Fully dependent. Physical deterioration, incontinence, gait abnormalities, spasticity, seizures (3%), tremor, weight loss, primitive reflexes, extrapyramidal signs. Psychiatric symptoms Delusions (15%) usually of a paranoid nature. Auditory and/or visual hallucinations (10 15%) which may be simple misidentification, and indicate rapid cognitive decline. Depression is common, requiring treatment in up to 20% of patients. Behavioural disturbances include aggression, wandering, explosive temper, sexual disinhibition, incontinence, excessive eating, and searching behaviour. Personality change often reflects an exaggeration of premorbid traits with coarsening of affect and egocentricity. Clinical subtypes and course Mayeux (1985) described four groups: The most common presentation is a gradual and progressive decline without distinguishing features. A group with early onset (<65), more aphasia and apraxia, a rapid course with severe intellectual decline, and poor survival rate. A group with extra-pyramidal signs, severe functional impairment, and associated psychotic symptoms. A benign group with little or no progression over a 4-yr follow-up. Factors associated with poor prognosis Greater severity of disease at presentation Being male Onset <65yrs Parietal lobe damage Prominent behavioural problems Severe focal cognitive deficits such as apraxia Observed depression Absence of misidentification syndrome
6 ALZHEIMER S DISEASE Assessment Detailed history An informant questionnaire such as the IQCODE can be helpful in this regard). Mental state examination Noting any clouding of consciousness (delirium), symptoms of depression, psychosis, etc. Cognitive testing is essential and may begin with a Mini Mental State Examination (MMSE), but later involve specific neuropsychological testing. Physical examination To detect presence or absence of focal signs, reflexes, and plantar responses, as well as gait disturbance and signs of Parkinson s disease. Blood tests (b p. 133). EEG useful to exclude delirium, Creutzfeldt Jakob disease (CJD), etc. to be considered in atypical cases only. Brain imaging: CT cortical atrophy, esp. over parietal and temporal lobes and ventricular enlargement. MRI (optima protocol) atrophy of grey matter (hippocampus, amygdala, and medial temporal lobe). Single photon emission tomography (SPET) reduced regional cerebral blood flow (rcbf) in temporal and posterior parietal lobes (also frontal lobes in advanced disease). PET 20 30% reduction in oxygen and glucose metabolism in temporal and posterior parietal lobes. Magnetic resonance spectroscopy (MRS) dn-acetylaspartatetypically reserved for use in combination with structural imaging where the diagnosis is in doubt.
7 138 CHAPTER 5 Organic illness Alzheimer s disease 3: pharmacological treatments 1 Acetylcholinesterase inhibitors (AChEIs) were the first drugs to be licensed for the treatment of DAT. They act by enhancing ACh at cholinergic synapses in the CNS, and in this way may slow progression of the disease, reducing time spent in full nursing care. They have beneficial effects on cognitive, functional, and behavioural symptoms of the disease and are recommended as first-line agents in the treatment of mild moderate DAT. (See Box 5.2.) First generation AChEIs Tacrine Developed in the 1980s; easily absorbed with a short ½ life; liver metabolism; non-linear kinetics; non-selective (also acts at parasympathetic receptors outside the CNS). Problems: Gastrointestinal tract (GIT) side-effects; iliver enzymes/hepatotoxicity; wide dose range, therefore unpredictable kinetics; 4x daily dosage. Second generation AChEIs Similar efficacy over 6mths; long-term efficacy unknown. Switching between agents is acceptable. Donepezil Piperidine derivative, developed in 1996; GIT absorbed with liver metabolism; long ½ life (70hrs); highly selective (acts centrally only); linear kinetics. Problems: GIT side-effects at high dose; bradycardia; GIT bleed (rare); contraindicated in asthma. Benefi ts: selective therefore dside-effects; no liver toxicity; predictable kinetics; narrow dose range; 1x daily dosage. Dose: 5 10mg/day. Rivastigmine Developed in 1998; short ½ life (12hrs); inhibits AChE and butyrylcholinesterase in CNS. Problems: GIT side-effects; 2 daily dosage. Benefi ts: Not metabolized by the liver and least likely to cause drug drug interactions. Dose: start with 1.5mg twice daily (BD); increase to 3 6mg BD now available in a modified release once daily (OD) form or 24hr patch (thought to be helpful in reducing GI side-effects). Galantamine Selectively inhibits AChE and acts as an allosteric ligand at nicotinic ACh receptors; metabolized in liver; short ½ life (5hrs); selective. Problems: 2 daily dosage. Dose: 4 12mg BD. NMDA-receptor partial antagonist The NMDA receptor binds excitatory glutamate in the CNS and has a role in LTP and learning/memory function. Memantine In Feb 2002, this new agent was approved in Europe for the treatment of moderately severe to severe DAT (MMSE 3 14). It is a non-competitive, PCP-site, N-methyl-D-aspartate (NMDA) antagonist that may protect neurons from glutamate-mediated excitotoxicity. Trials show benefits of memantine augmentation of donepezil. Cochrane review indicates use in DAT, vascular, and mixed dementia. Other (possible) treatment strategies Although only at experimental stages, there is some evidence for other approaches to DAT.
8 ALZHEIMER S DISEASE 3: PHARMACOLOGICAL TREATMENTS 139 These include: antioxidants (vitamin E; selegiline); anti-inflammatories; secretase inhibitors; metal chelators; amyloid-b-peptide vaccination; cholesterol-lowering drugs; red wine (!). There is ongoing work looking at possible neuroprotective effects of lithium. Box 5.2 NICE guidance on drug treatment for Alzheimer s disease donepezil, rivastigmine, and galantamine (No 19) The three drugs donepezil, rivastigmine, and galantamine should be made available in the NHS as one component of the management of those people with mild and moderate Alzheimer s disease (AD) whose MMSE score is above 12 points, under the following conditions: Diagnosis that the form of dementia is AD must be made in a specialist clinic according to standard diagnostic criteria. Assessment in a specialist clinic, including tests of cognitive, global, and behavioural functioning and of activities of daily living, should be made before the drug is prescribed. Clinicians should also exercise judgement about the likelihood of compliance; in general, a carer or care-worker who is in sufficient contact with the patient to ensure compliance should be a minimum requirement. Only specialists (including old age psychiatrists, neurologists, and care of the elderly physicians) should initiate treatment. Carers views of the patient s condition at baseline and follow-up should be sought. If GPs are to take over prescribing, it is recommended that they should do so under an agreed shared-care protocol with clear treatment end points. A further assessment should be made, usually 2 4 months after reaching maintenance dose of the drug. Following this assessment, the drug should be continued only where there has been an improvement or no deterioration in MMSE score, together with evidence of global improvement on the basis of behavioural and/or functional assessment. Patients who continue on the drug should be reviewed by MMSE score and global, functional, and behavioural assessment every 6 months. The drug should normally only be continued while their MMSE score remains above 12 points, and their global, functional, and behavioural condition remains at a level where the drug is considered to be having a worthwhile effect. When the MMSE score falls below 12 points, patients should not normally be prescribed any of these three drugs. Any review involving MMSE assessment should be undertaken by an appropriate specialist team, unless there are locally agreed protocols for shared care. 1 Scarpini E, Scheltens P, Feldman H (2003) Treatment of Alzheimer s disease: current status and new perspectives. Lancet (Neurol) 2:
WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationCognitive disorders. Dr S. Mashaphu Department of Psychiatry
Cognitive disorders Dr S. Mashaphu Department of Psychiatry Delirium Syndrome characterised by: Disturbance of consciousness Impaired attention Change in cognition Develops over hours-days Fluctuates during
More informationDelirium & Dementia. Nicholas J. Silvestri, MD
Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts
More informationDementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician
Dementia Aetiology, pathophysiology and the role of neuropsychological testing Dr Sheng Ling Low Geriatrician Topics to cover Why is dementia important What is dementia Differentiate between dementia,
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationAlzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,
2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,
More informationOLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.
Psychiatric disorders of the elderly OLD AGE PSYCHIATRY Dementia Depression Delusional disorder/late onset schizophrenia Delirium Dementia definition LOCALISATION OF CEREBRAL FUNCTION Impairment of multiple
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More informationDifferentiating Dementia Diagnoses
Differentiating Dementia Diagnoses Waitemata PHO 21 October 2014 Dr Michal Boyd, RN, NP, ND Nurse Practitioner Older Adults School of Nursing & Freemasons Dept. of Geriatric Medicine The University of
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationDementia and Alzheimer s disease
Since 1960 Medicine Korat โรงพยาบาลมหาราชนครราชส มา Dementia and Alzheimer s disease Concise Reviews PAWUT MEKAWICHAI MD DEPARTMENT of MEDICINE MAHARAT NAKHON RATCHASIMA HOSPITAL 1 Prevalence Increase
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationIntroduction to Dementia: Diagnosis & Evaluation. Created in March 2005 Duration: about 15 minutes
Introduction to Dementia: Diagnosis & Evaluation Created in March 2005 Duration: about 15 minutes Axel Juan, MD The Geriatrics Institute axel.juan@med.va.gov 305-575-3388 Credits Principal medical contributor:
More informationDr Georgina Train Consultant Psychiatrist EMDASS service and Continuing Care.
Dr Georgina Train Consultant Psychiatrist EMDASS service and Continuing Care. Consultant Psychiatrist of both General adult and Old Age Psychiatry. Work with Memory Service and a Continuing Care ward.
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationA Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies
A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies Lynda Mackin, PhD, AGPCNP-BC, CNS University of California San Francisco School of Nursing 1 Alzheimer s
More information7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery
ABNORMAL PSYCHOLOGY SEVENTH EDITION Oltmanns and Emery PowerPoint Presentations Prepared by: Ashlea R. Smith, Ph.D. This multimedia and its contents are protected under copyright law. The following are
More informationThe Person: Dementia Basics
The Person: Dementia Basics Objectives 1. Discuss how expected age related changes in the brain might affect an individual's cognition and functioning 2. Discuss how changes in the brain due to Alzheimer
More informationDiagnosis and management of non-alzheimer dementias. Melissa Yu, M.D. Department of Neurology
Diagnosis and management of non-alzheimer dementias Melissa Yu, M.D. Department of Neurology AGENDA Introduction When to think of alternate diagnoses Other forms of dementia Other reasons for confusion
More informationDelirium, Dementia, and Amnestic Disorders. Dr.Al-Azzam 1
Delirium, Dementia, and Amnestic Disorders Dr.Al-Azzam 1 Introduction Disorders in which a clinically significant deficit in cognition or memory exists The number of people with these disorders is growing
More informationDementia. Amber Eker, MD. Assistant Professor Near East University Department of Neurology
Dementia Amber Eker, MD Assistant Professor Near East University Department of Neurology Dementia An acquired syndrome consisting of a decline in memory and other cognitive functions Impairment in social
More informationDementia Diagnosis Guidelines Primary Care
Dementia Diagnosis Guidelines Primary Care Dementia Diagnosis Primary Care Guidelines Introduction Dementia is a long term condition, which primarily affects people over the age of 65 (late on-set dementia)
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
diagnosis and assessment bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationCaring Sheet #11: Alzheimer s Disease:
CARING SHEETS: Caring Sheet #11: Alzheimer s Disease: A Summary of Information and Intervention Suggestions with an Emphasis on Cognition By Shelly E. Weaverdyck, PhD Introduction This caring sheet focuses
More informationClinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)
Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following
More informationIf you have dementia, you may have some or all of the following symptoms.
About Dementia Dementia may be caused by a number of illnesses that affect the brain. Dementia typically leads to memory loss, inability to do everyday things, difficulty in communication, confusion, frustration,
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationSTUDENT GUIDELINES FOR DIAGNOSIS OF DEMENTIA
STUDENT GUIDELINES FOR DIAGNOSIS OF DEMENTIA What is dementia? Dementia is characterised by a slow, sometimes stepwise, deterioration in the elderly person s mental, physical and social functioning. It
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationDementia: Diagnosis and Treatment
Dementia: Diagnosis and Treatment Outline 1. Risk factors and definition of dementia 2. Types of Dementias 3. MMSE and testing 4. Treatment options Cognitive decline with aging Mild changes in memory and
More informationWhat is dementia? alzheimers.org.uk
alzheimers.org.uk What is dementia? If you, or a friend or relative, have been diagnosed with dementia, you may be feeling anxious or confused. You may not know what dementia is. This factsheet should
More informationDementia NICE Guidelines Update. Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018
Dementia NICE Guidelines Update Key points for primary care - NICE guideline (June 2018 update ) 26 September 2018 How NICE guidelines are reviewed Multidisciplinary guideline committee established Review
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE 1 Guideline title SCOPE Dementia: the management of dementia, including the use of antipsychotic medication in older people 1.1 Short title Dementia 2 Background
More informationThe Basics of Alzheimer s Disease
2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU
More informationAlzheimer Disease and Related Dementias. Alzheimer Society of Manitoba Dr. David Strang
Alzheimer Disease and Related Dementias Alzheimer Society of Manitoba Dr. David Strang What is Dementia? Dementia is a syndrome symptoms include loss of memory, judgment and reasoning, and changes in mood
More informationDementia and Delirium
Dementia and Delirium LPT Gondar Mental Health Group www.le.ac.uk Dementia and Delirium WTINP Chapter 4.6 Introduction - areas to be covered Delirium Definition and causes Clinical features Management
More informationDementia Chronic Brain Failure The forgotten cardiovascular disease Clare Hawley 2015
Dementia Chronic Brain Failure The forgotten cardiovascular disease Clare Hawley 2015 MB ChB, MRCGP, PG Dip Cardiol, PG Cert Med Ed Associate Specialist Cardiology Chesterfield Royal Hospital GPwSI Refractory
More informationDr Roger Cable NHS Dumfries and Galloway
Dr Roger Cable NHS Dumfries and Galloway Young Onset Dementia Statistics What is dementia Diagnosing dementia History Examination Tests Subtypes of dementia 315000 Cost of dementia (Alzheimer s society)
More informationDEMENTIA. Szabolcs Szatmári. Tg. Mureş Marosvásárhely Romania 4/18/ :59 AM
DEMENTIA Szabolcs Szatmári Tg. Mureş Marosvásárhely Romania Dementia from Latin de- "apart, away" + mens (genitive mentis) "mind" MORE GRAY HAIR AND LESS GRAY MATTER Daryl R. Gress Cognitive decline
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationDementia and cognitive decline
Dementia and cognitive decline Expert Briefing Su Ray and Dr Susan Davidson Research Department Together, we can help everyone to love later life 01 Brain basics Normal ageing, cognitive impairment and
More informationDementia. Dr Maria Foundas Consultant Physician. Training support Skills development Competency Assessment Scholarships Education
Dementia Dr Maria Foundas Consultant Physician Training support Skills development Competency Assessment Scholarships Education Preamble and disclaimer These slides are made available by the Western Australian
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationPharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
More informationWhat is dementia? What is dementia?
What is dementia? What is dementia? What is dementia? Dementia is an umbrella term for a range of progressive conditions that affect the brain. It has been identified that there are over 200 subtypes of
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationDiagnosis of Dementia: Clinical aspects
Diagnosis of Dementia: Clinical aspects George Tadros Consultant in Old Age Psychiatry Professor of Old Age Liaison Psychiatry, Warwick Medical School, University of Warwick Visiting Professor of Mental
More informationMemory Loss, Dementia and Alzheimer's Disease: The Basics
Memory Loss, Dementia and Alzheimer's Disease: The Basics What is memory loss? What is age-related memory loss? Typical changes Typical age-related changes involve: Making a bad decision once in a while
More informationNeuroimaging for dementia diagnosis. Guidance from the London Dementia Clinical Network
Neuroimaging for dementia diagnosis Guidance from the London Dementia Clinical Network Authors Dr Stephen Orleans-Foli Consultant Psychiatrist, West London Mental Health NHS Trust Dr Jeremy Isaacs Consultant
More informationAlzheimer s disease dementia: a neuropsychological approach
Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationCurrent Treatments for Dementia and Future Prospects. James Warner St Charles Hospital, London
Current Treatments for Dementia and Future Prospects James Warner St Charles Hospital, London Dementia Cognitive Non-cognitive (BPSD) Memory orientation language other cognitive abilities praxis planning
More informationFTD basics! Etienne de Villers-Sidani, MD!
FTD basics! Etienne de Villers-Sidani, MD! Frontotemporal lobar degeneration (FTLD) comprises 3 clinical syndromes! Frontotemporal dementia (behavioral variant FTD)! Semantic dementia (temporal variant
More informationDementia Training Session for Carers. By Dr Rahul Tomar Consultant Psychiatrist
Dementia Training Session for Carers By Dr Rahul Tomar Consultant Psychiatrist Dementia in the UK: Facts & Figures National Dementia strategy launched in 2009 800,000 people living with dementia (2012)
More informationWhat is dementia? What is dementia?
What is dementia? What is dementia? What is dementia? Dementia is an umbrella term for a range of progressive conditions that affect the brain. There are over 200 subtypes of dementia, but the five most
More informationDIFFERENTIAL DIAGNOSIS OF NEUROCOGNITIVE DISORDERS
DIFFERENTIAL DIAGNOSIS OF NEUROCOGNITIVE DISORDERS Maria D. Llorente MD Associate Chief of Staff, Mental Health Washington DC VA Medical Center Professor of Psychiatry, Georgetown University School of
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationAlzheimer s Dementia May 5, 2008
Sharon Leigh, PharmD. BCPS Alzheimer s Dementia Page - 1 - I. Dementia vs. delirium Alzheimer s Dementia May 5, 2008 Dementia Gradual onset (insidious) Chronic illness progressing over years Irreversible
More informationGERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences GERIATRIC MENTAL HEALTH AND MEDICATION TREATMENT RUTH KOHEN ASSOCIATE PROFESSOR UW DEPARTMENT OF PSYCHIATRY 5-4-2017
More informationThe Psychopharmacology of Alzheimer s Disease. Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school
The Psychopharmacology of Alzheimer s Disease Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school Overview of Alzheimer s Disease Alzheimer s is a progressive degenerative disease Prevalence
More informationAlzheimer s Disease - Dementia
- Dementia Neurocognitive disorder with dysfunction or loss of " Memory " Orientation " Attention " Language " Judgment " Reasoning Other characteristics that can manifest " Personality changes " Behavioral
More informationOrganic mental disorders
Organic mental disorders F00-F09 Organic, including symptomatic, mental disorders This block comprises a range of mental disorders grouped together on the basis of their having in common a demonstrable
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationChronic Traumatic Encephalopathy Provider and Parent Essentials
Chronic Traumatic Encephalopathy Provider and Parent Essentials Concussion Global Cast July 30, 2014 John Lockhart, MD Seattle Children s Hospital Chronic Traumatic Encephaly (CTE) Working Definition Chronic
More informationPrimary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia
Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the
More informationDementia and Delirium: A Neurologist s Approach to Altered Mental Status. Case 1 4/7/11. Which of the following evaluations is your next step?
Dementia and Delirium: A Neurologist s Approach to Altered Mental Status S. Andrew Josephson, MD Director, Neurohospitalist Program Medical Director, Inpatient Neurology University of California San Francisco
More informationMOVEMENT DISORDERS AND DEMENTIA
MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic
More informationDementia. Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
Dementia Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine What is Dementia? Dementia is a general term referring to a decline in cognitive/mental functioning; this decline
More informationMental Health Disorders Civil Commitment UNC School of Government
Mental Health Disorders 2017 Civil Commitment UNC School of Government Edward Poa, MD, FAPA Chief of Inpatient Services, The Menninger Clinic Associate Professor, Baylor College of Medicine NC statutes
More informationNon Alzheimer Dementias
Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,
More informationDementia: The Role of Neuropsychology and Finding the Right Diagnosis
Dementia: The Role of Neuropsychology and Finding the Right Diagnosis Robert E. Cohen, PsyD Director - Department of Neuropsychology Orlando Health Memory Disorder Clinic OBJECTIVES: Discuss the role of
More informationDementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.
Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:
More information10/17/2017. Causes of Dementia Alzheimer's Disease Vascular Dementia Diffuse Lewy Body Disease Alcoholic Dementia Fronto-Temporal Dementia Others
1 Dementia Dementia comes from the Latin word demens, meaning out of mind. It is the permanent loss of multiple intellectual functions. It is progressive deterioration of mental powers accompanied by changes
More informationPROJECTION: Worlds dementia population is expected to triple by 2050
DEMENTIA C L I S K C O N S U LTA N T P H Y S I C I A N I N A C U T E M E D I C I N E A N D G E R I AT R I C M E D I C I N E, B A R N E T H O S P I TA L, R O YA L F R E E N H S F O U N D AT I O N T R U
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationDementia: How to explain the diagnosis to patients and relatives
GPHot Topics (April 2017): Dementia: How to explain the diagnosis to patients and relatives mohammad somauroo Consultant Physician with specialist interest in Community Geriatrics Royal Liverpool and Broadgreen
More informationPalliative Approach to the Person with Advanced Dementia
Mid North Coast Rural Palliative Care Project Link Nurse Education 2004 Palliative Approach to the Person with Advanced Dementia Anne Sneesby CNC - ACAT To care for the dying is a very human opportunity
More informationCHAPTER 15: NEUROCOGNITIVE DISORDERS KEY TERMS. Acetylcholine A neurotransmitter that appears to be involved in learning and memory.
CHAPTER 15: NEUROCOGNITIVE DISORDERS KEY TERMS Acetylcholine A neurotransmitter that appears to be involved in learning and memory. Adult Memory and Information Processing Battery (AMIPB) A neuropsychological
More informationAlzheimer s disease. The facts in brief
Alzheimer s disease Dementia is an umbrella term used to describe various conditions which damage brain cells and lead to a loss of brain function over time. Dementia causes a progressive decline in a
More informationDementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE
Dementia ALI ABBAS ASGHAR-ALI, MD STAFF PSYCHIATRIST MICHAEL E. DEBAKEY VA MEDICAL CENTER ASSOCIATE PROFESSOR BAYLOR COLLEGE OF MEDICINE Objectives At the conclusion of the session, participants will be
More information212 Index C-SB-13,
Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationUnderstanding Dementia
Dementia Handbook for Carers Essex Understanding Dementia What is dementia? 1 Summary of dementia symptoms 4 Medication and treatment 5 1 Dementia is the name for several conditions that lead to the progressive
More informationDementia Care Pathway
Document level: West Locality Code: CC41 Issue number: 1 Dementia Care Pathway Lead executive Authors details Type of document Target audience Document purpose Medical Director Dr Anushta Sivananthan Dr
More informationVascular Dementia. Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center
Vascular Dementia Laura Pedelty, PhD MD The University of Illinois at Chicago and Jesse Brown VA Medical Center none Disclosures Objectives To review the definition of Vascular Cognitive Impairment (VCI);
More informationDEMENTIA ANDREA BERG, MD
DEMENTIA ANDREA BERG, MD What Is Dementia? Decline in memory, language, problem-solving and other cognitive skills that affects a persons ability to perform everyday activities Progressive and disabling
More informationCommon Forms of Dementia Handout Package
Common Forms of Dementia Handout Package Common Forms of Dementia 1 Learning Objectives As a result of working through this module, you should be better able to: 1. Describe clinical features of 4 major
More informationDementia. Team Members: Abdulaziz Alsalem, Khalid Al-Qahtani, Dania Alkelabi, Sarah Alshamrani
Dementia Objectives: differentiate delirium from dementia differentiate Mild Cognitive Impairment from Dementia become familiar with common dementia syndromes, and available treatments Team Members: Abdulaziz
More informationRoger E. Kelley, M.D. Professor and Chairman Department of Neurology Tulane University School of Medicine New Orleans, Louisiana
Roger E. Kelley, M.D. Professor and Chairman Department of Neurology Tulane University School of Medicine New Orleans, Louisiana FINANCIAL DISCLOSURE No potential conflict of interest to disclose. OBJECTIVES
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationConfronting the Clinical Challenges of Frontotemporal Dementia
Confronting the Clinical Challenges of Frontotemporal Dementia A look at FTD s symptoms, pathophysiology, subtypes, as well as the latest from imaging studies. By Zac Haughn, Senior Associate Editor Ask
More informationP20.2. Characteristics of different types of dementia and challenges for the clinician
P20.2. Characteristics of different types of dementia and challenges for the clinician, professor Danish Dementia Research Center Rigshospitalet, University of Copenhagen (Denmark) This project has received
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health
ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and
More information